ClinicalTrials.gg
CompletedNCT06380153Updated Dec 4, 2025

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

A Phase 1 interventional study of Hemay005 in Psoriasis, sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Hemay005 in Psoriasis — 1 open to participants now, 1 under way, none of them phase 3. Hemay005 · Psoriasis.

Enrollment
5th of 10
26 · median 25
Started
2024
with 3 others
Phase 1
8 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
4 of 10
Ganzhou Hemay Pharmaceutical Co., Ltd

Among the 10 studies testing Hemay005 in Psoriasis, this one is the 5th largest by enrollment, is one of 4 that started in 2024, is one of 8 in phase 1, and was the 7th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 10 studies testing Hemay005 in Psoriasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Hemay005

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Hemay005 in Psoriasis, or all of them as a file.
02

Study summary

The aim of this study was to evaluate the pharmacokinetics of Hemay005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication regimens for patients with renal impairment.

Read the detailed description

To evaluate the pharmacokinetics and safety of Hemay 005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication regimens for patients with renal impairment.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Fully understand the content, process and possible adverse reactions of the trial before the trial, and be able to complete the study and sign the according to the requirements of the trial protocol;

    2.adults of both sexes aged 18-70 years old (both ends, whichever is based on written informed consent);

    3. The body weight of male subjects was not less than 50 kg and that of female subjects was not less than 45 kg. (BMI) : 19-32 kg/m2 (including cut-off value);

    4.The rate (CLcr, calculated by Cockcroft-Gault formula) of the subjects met the CKD staging criteria of the corresponding groups, namely mild renal impairment: 60≤CLcr\<90 mL/min; Moderate renal impairment: 30≤CLcr\<60mL/min. At the same time, according to the investigator's judgment, the creatinine clearance rate of the subjects was not expected to change significantly by the end of the study.

    5. Stable renal function: the interval between two creatinine tests was at least 3 days (30 days before the first test result was acceptable), and the fluctuation value of serum creatinine results between the two tests (calculated by the formula: (the second result-the first result)/the first result) was less than 30%;

    6.no new concomitant medications in the 2 weeks before screening, no adjustment in the treatment regimen (including the type, dose, or frequency of medications) for underlying diseases in the 4 weeks before screening, and no change in the treatment regimen (except for drugs used temporarily on demand) during the study (except as specified in the protocol), or no medication was used;

    7.In addition to renal impairment and complications, the investigators were in good physical condition according to medical history inquiry, vital signs, physical examination, laboratory tests (blood routine, urine routine, stool routine, blood biochemistry, coagulation function, blood pregnancy (only female), 12-lead , chest X-ray, abdominal color Doppler ultrasound, etc.), and no other abnormalities.

Exclusion criteria

Exclusion Criteria:

  • 1.(Inquired) The subject has any of the following conditions: acute kidney failure, a history of kidney transplantation, or a need for kidney transplantation or any type of dialysis during the planned trial period; Patients with urinary incontinence or anuria; Patients with obstructive urinary tract diseases (such as urinary tract obstruction caused by urinary calculi, urinary tract obstruction caused by abdominal space occupying lesions, etc.), and the investigator thought that they were not suitable;

    2. (Inquiry) In addition to the disease causing renal impairment, patients with serious acute or chronic diseases of other vital organs within 1 year prior to screening, including but not limited to diseases of the nervous system, cardiovascular system, blood and lymphatic system, immune system, liver, gastrointestinal system, respiratory system, metabolic system, skeletal system and other systems, who were judged by the investigator to be not suitable for the trial;

    3. (Inquiry) Any of the following occurred in the 6 months prior to study entry: Myocardial infarction, Congenital long syndrome, Torsades de pointes (including sustained ventricular tachycardia and ventricular fibrillation), right bundle branch block and left anterior hemiblock (bifascicular block), Unstable angina pectoris, coronary artery/peripheral artery bypass grafting, (NYHA) class III or IV congestive heart failure, cerebrovascular accident, , or pulmonary embolism;

    4. (inquiring) patients with a history of depression or suicidal tendencies;

    5. (inquiry) patients who had severe gastrointestinal diseases or had digestive system surgery within 3 months before screening, which affected drug absorption according to the investigator;

    6.(inquiry) blood loss or donation of more than 400mL within one month before screening, or red blood cell transfusion;

    7. Screening laboratory test results met any of the following: (a) (ALT) >2 times the normal value; (b) total >1.5 times the normal value; (c) \<1.3×109/L; (d) \<80g/L; (e) count \<80×109/L;

    8.(inquiry) with specific allergic history (asthma, urticaria, eczema, etc.), or allergic condition (such as allergic to two or more drugs, foods or pollens), or known allergic to PDE4 inhibitors (such as apast, roflumilast, etc.);

    9. (queried) drug users in the past 3 years or drug abuse in the past 5 years;

    10. screening positive for drug abuse (excluding those screened positive for drug abuse due to concomitant medications);

    11. with positive breath alcohol test (alcohol concentration >0mg/L);

    12. (inquired) drank more than 14 units of alcohol per week in the 3 months before screening (1 unit = 17.7 mL ethanol, i.e. 1 unit = 354 mL of 5% beer or 44 mL of 40% liquor or 147 mL of 12% wine), or could not abstain from alcohol during the study;

    13.(inquired) smoked more than 5 cigarettes per day in the 3 months before screening, or could not stop using any tobacco products during the study;

    14. (questionnaire) consuming excessive amounts of tea, coffee and/or caffeine-rich beverages (> 8 cups, 1 cup =250 mL) per day in the previous 3 months;

    15. , , and syphilis tests have one or more clinical significance;

    16. (inquiry) who had participated in and used other drug/device clinical trials within 3 months before screening;

    17. (inquiry) use of any drugs (e.g., inductors-barbiturates, pioglitazone, carbamazepine, phenytoin, ) that induce or inhibit hepatic drug-metabolizing enzymes within 30 days before screening; Inhibitors: SSRI antidepressants, cimetidine, diltiazem macrolides, nitroimidazole, sedative hypnotics, verapamil, fluoroquinolones, antihistamines, isoniazid);

    18. (inquiry) who had used prescription drugs, over-the-counter drugs, health supplements, herbal products or vaccines other than those used to treat renal impairment and other concomitant diseases within 2 weeks before screening;

    19. (inquiry) consumed any caffeine/xanthine/food or drink (such as strong tea, coffee, chocolate, cola, animal organs, grapefruit, dragon fruit, mango, etc.) rich in caffeine/xanthine/which may affect the absorption, distribution, metabolism, and excretion of the drug in the investigator's decision from screening to -1 day of admission, or could not stop consuming the above food or drink during the study;

    20. (inquiry) pregnant or lactating women, or subjects (including male subjects) who have plans to have children or to donate sperm or eggs from two weeks before the study to six months after the last dose of the study, and who are unwilling or unable to use effective ;

    21.(inquiry) unable to eat or have swallowing difficulties, have special dietary requirements and/or cannot follow a uniform diet;

    22. (inquiry) with a history of epileptic seizures;

    23. (inquiry) can not tolerate venipuncture and/or have a history of dizziness;

    24.subjects with other factors considered by the investigator to be ineligible for the trial.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Mild renal impairment group

    15mg/tablet,Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

    Drug: Hemay005

  • Experimental
    Moderate renal impairment group

    15mg/tablet,Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

    Drug: Hemay005

  • Experimental
    Healthy subjects

    15mg/tablet,Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

    Drug: Hemay005

Interventions

  • 15mg/tablet,Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

    Also known as: Hemay005 tablet

06

What researchers measure

Primary outcomes

  1. Relevant pharmacokinetic parameters,Peak Plasma Concentration(Cmax)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

  2. Relevant pharmacokinetic parameters,Area under the plasma concentration versus time curve(AUC0-t)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

  3. Relevant pharmacokinetic parameters,Area under the curve from time 0 extrapolated to infinite time (AUC0-inf)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

  4. Relevant pharmacokinetic parameters,half-life (T1/2)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

  5. Relevant pharmacokinetic parameters,clearance (CL/F)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

  6. Relevant pharmacokinetic parameters,volume of distribution (Vz/F)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

  7. Relevant pharmacokinetic parameters ,Renal clearance rate(CLr)

    All subjects who receive the drug will be analyzed for pharmacokinetic

    Time frame: Day1-Day6

07

Study locations

1 site
  • Union Hospital of Tongji Medical College; Huazhong University of Science and Technology
    Wuhan, Hubei, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Apr 2025, 11 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is close to that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 23, 2024
StartActual
May 7, 2024
Primary completionActual
Apr 16, 2025
CompletionActual
Apr 16, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06380153
Lead sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
May 7, 2024
Primary completion
Apr 16, 2025
Completion
Apr 16, 2025
Last update
Dec 4, 2025

Study contacts

Weiyong Li
principal investigator · Study Principal Investigator

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hemay005

Start the discussion